Search
SOBI-003
go.drugbank.com/drugs/DB15451InvestigationalIt is under investigation in clinical trial NCT03811028 (A Study to Assess the Safety, Tolerability, and Efficacy of Long-term SOBI003 Treatment in Pediatric MPS IIIA Patients).
Niraparib
go.drugbank.com/drugs/DB11793ApprovedInvestigationalNiraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First appr...
Gadobenic acid
go.drugbank.com/drugs/DB00743ApprovedInvestigational[A263166] As gadobenate dimeglumine is specifically taken up by hepatocytes and excreted through the biliary system, it is a useful contrast agent for liver MRI.
Clesrovimab
go.drugbank.com/drugs/DB18877Approved[A273953,A273978] Clesrovimab-cfor was approved by the US FDA in June 2025 for use in infants prior to or during their first RSV season.[L53228,L53233]
Relacorilant
go.drugbank.com/drugs/DB14976ApprovedInvestigational[L56089] Relacorilant was approved by the US FDA on March 25, 2026, for use in combination with [paclitaxel] in patients with certain platinum-resistant cancers.[L56093,L56089]
Fludiazepam
go.drugbank.com/drugs/DB01567IllicitInvestigationalIt is a scheduled drug in the U.S., but is approved for use in Japan.
Tibolone
go.drugbank.com/drugs/DB09070ApprovedInvestigationalIn June 2006, Organon Pharmaceuticals announced the receipt of a Not Approvable Letter from the U.S.
Nylidrin
go.drugbank.com/drugs/DB06152ApprovedWithdrawnTherefore, the FDA has withdrawn nylidrin from the U.S. market [L2286].
Debrisoquine
go.drugbank.com/drugs/DB04840ApprovedAn adrenergic neuron-blocking drug similar in effects to guanethidine. It is also noteworthy in being a substrate for a polymorphic cytochrome P-450 enzyme. Persons with certain isoforms of this enzyme are unable to properly metabolize t...
Tuparstobart
go.drugbank.com/drugs/DB19118InvestigationalTuparstobart is under investigation in clinical trial NCT05287113 (Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-line Treatment in Participants With Pd-l1-positive (CPS